BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Benzinga · 2d ago
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.